Today’s must-listen episode includes an in-depth review of two key papers plus a ‘mind boggling’ paper of the week, Quick Bites and an interview with Professor Dorothy Keefe on Optimal Care Pathways.
Eva talks us through the I-SPY 2 trial and Hans is focused on the National Lung Matrix trial. Eva also has a ‘mind boggling’ paper of the week on the #MedBikini controversy.
This week we are very lucky to have a special interview with the incredible Professor Dorothy Keefe, Medical Oncologist and CEO of Cancer Australia. In this episode Dorothy and Craig discuss recently published papers on Optimal Care Pathways but you can listen to the extended interview ‘The OJC Meets Dorothy Keefe’ here where Dorothy passionately discusses her priorities for Cancer Australia, disparity and what she hopes will be her lasting legacy leading the Australian national government agency for cancer.
We also have Quick Bites on pregnancy after breast cancer, a diagnostic biopsy-adapted immunoscore and PD1 blockade resistance.
With the usual top quality banter, papers you won’t hear of anywhere else and expert analysis from our Hosts, you are in for another great episode of The Oncology Journal Club!
About The Oncology Journal Club:
We have taken an old concept and updated it with a new format. In each episode a team of expert contributors will review topical journal papers and interview special guests who are leaders in their fields to help keep you informed of the latest developments on the go.
With The Oncology Podcast – and The Oncology Journal Club in particular – we are aiming to deliver oncology news differently,” Rachael Babin, Editor-in-Chief, Oncology News.
Today’s episode is hosted by Professor Eva Segelov, from Monash University. Eva is joined by Dr Craig Underhill from Albury-Wodonga and Professor Hans Prenen from Antwerp, Belgium. We hope you enjoy listening and find this a valuable and entertaining resource. Please let us know what you think!
This Week’s Papers:
- I-SPY2 Trial Consortium. Association of Event-Free and Distant Recurrence–Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial. JAMA Oncol. Published online July 23, 2020. doi:10.1001/jamaoncol.2020.2535. Access online here.
- Hardouin, Scott et al. Prevalence of unprofessional social media content among young vascular surgeons. Journal of Vascular Surgery, Volume 72, Issue 2, 667 – 671. Access online here.
- Middleton, G., Fletcher, P., Popat, S. et al. The National Lung Matrix Trial of personalized therapy in lung cancer. Nature (2020). Access online here.
In today’s episode we have a special interview on Optimal Care Pathways with Craig Underhill and Dorothy Keefe, CEO of Cancer Australia. Amongst other things, they discuss the following papers:
- Bergin RJ, et al. Concordance between Optimal Care Pathways and colorectal cancer care: Identifying opportunities to improve quality and reduce disparities. J Eval Clin Pract. 2020;26(3):918-926. doi:10.1111/jep.13231. Access online here.
- Marvelde, Luc te., et al. Alignment with Indices of A Care Pathway Is Associated with Improved Survival: An Observational Population-based Study in Colon Cancer Patients. The Lancet. Volume 15, October 2019. Access online here.
- Lambertini, Matteo et al. Pregnancy After Breast Cancer in Patients With Germline BRCA Mutations. Journal of Clinical Oncology. Published online July 16, 2020. Access online here.
- El Sissy, Carine. A diagnostic biopsy-adapted immunoscore predicts response to neoadjuvant treatment and selects patients with rectal cancer eligible for a watch-and-wait strategy. Clin Cancer Res. 2020 Jul 15;clincanres.0337.2020. doi: 10.1158/1078-0432.CCR-20-0337. Online ahead of print. Access online here.
- Andrews, Lawrence P et al. Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding. Science Immunology. 17 Jul 2020: Vol. 5, Issue 49, eabc2728. DOI: 10.1126/sciimmunol.abc2728. Access online here.
- Rozlytrek® (entrectinib) for locally advanced or metastatic non-small cell lung cancer patients with a c-ROS proto-oncogene 1 (ROS1) gene rearrangement
- Lorviqua® (lorlatinib) for the treatment of metastatic anaplastic lymphoma kinase positive non-small cell lung cancer in patients who have disease progression following other treatment options
- Lynparza® (olaparib) for the treatment of high-grade serous ovarian cancer, fallopian tube cancer and primary peritoneal cancer
There’s more information here.
This Week’s Team:
Professor Eva Segelov
Professor Eva Segelov is a Medical Oncologist and is Director of Oncology at Monash University and Monash Health, Melbourne, Victoria, previously Senior Medical Oncologist at St Vincent’s Hospital, St Vincent’s Private Hospital and St Vincent’s Clinic and Associate Professor of Medicine, University of New South Wales.
Eva has an interest in academic clinical trials in GI and breast cancer and has been a member of the AGITG since 2003. She has clinical trials expertise, links with national and international trials groups, and extensive experience with adult medical education.
Professor Hans Prenen
Professor Hans Prenen is a medical oncologist and head of the phase 1 – early clinical trials unit at the Antwerp University Hospital in Belgium. He is a member of several scientific organisations, published many scientific oncology papers in prestigious journals and is regularly invited for lectures at national and international meetings. His interests are clinical trials and translational research with a focus on digestive oncology.
Dr Craig Underhill
Dr Craig Underhill completed his Bachelor of Medicine and Surgery in 1987 at Melbourne University. He completed medical oncology training in Melbourne and worked as the Senior Clinical Research Registrar at Guy’s Hospital, London.
In 1998 arrived in Albury-Wodonga and established a medical oncology practice and clinical trials unit which has developed expertise and infrastructure to ensure the initiation of high quality trials. The research Unit lead by Dr Underhill has twice been awarded NSW Premier’s Award for Innovation in Cancer Clinical Trials, the inaugural award in 2009 and then again in 2012.
Dr Underhill chaired a working party that was instrumental in securing $65 million in federal funding for The Albury Wodonga Regional Cancer Centre which opened in September 2016.
Dr Underhill is the VCCC Regional Oncology Lead and advocates for the increased access to clinical trials for regional Victorians and leads the VCCC teletrials program.
Professor Keefe is the CEO of Cancer Australia, and an honorary Clinical Professor in the School of Medicine at the University of Adelaide. She has had a long career as a Medical Oncologist, and Professor of Cancer Medicine. Her areas of expertise include gastrointestinal toxicity of cancer treatment, Supportive Care in Cancer more broadly, Medical Leadership and Health Reform, and she has published extensively in the Supportive Care literature. She has a long-standing commitment to the Multinational Association of Supportive Care in Cancer (MASCC), and is a past-president. All her work is focused on improving outcomes for patients .
Rachael Babin is Editor-in-Chief of The Oncology Newsletter and Publisher of www.oncologynews.com.au. For regular oncology updates for healthcare professionals, please subscribe to The Oncology Newsletter.
With thanks to Eva Segelov, Craig Underhill, Hans Prenen, Dorothy Keefe and Graham Knowles.